Shijiazhuang Yishengtang Medical Product Co., Ltd. was established in August 2004. The factory is located in the Luquan Green Island Economic Development Zone of Shijiazhuang, covering an area of 35000 square meters. Shijiazhuang Yishengtang Medical Supplies Co., Ltd. is a national high-tech enterprise, the National Development and Reform Commission Biomedical Engineering High-tech Demonstration Base, the International Science and Technology Cooperation Base for Polysaccharide Biomedical Materials of the Ministry of Science and Technology of the People's Republic of China, the Hebei Academician Workstation, the Hebei Provincial Department of Science and Technology Polysaccharide Biomedical Materials Engineering Technology Center, the Hebei Provincial Development and Reform Commission Enterprise Technology Center,  The drug (medical device) inspector training base of Hebei Provincial Drug Administration, the medical device director unit of the Medical and Pharmaceutical Chamber of Commerce of the Chinese Federation of Industry and Commerce, and the enterprise director unit of the Chinese Society of Biotechnology. The president unit of Hebei Medical Device Industry Association is a technical enterprise focusing on the research and development, production and sales of high-end biomedical materials, and has a complete industrial operation system of Class III and Class II medical devices. Since the establishment of the company, various businesses have developed rapidly and achieved good results.

The company's new products are based on clinical demand, mainly for new biomedical materials with high added value and high technology content, including biodegradable biomedical materials and their derivatives (such as chitosan, starch, cellulose products, etc.). Biomedical materials are the new main component of the biological industry, and are a new sunrise industry involving multiple disciplines, The clinical demand of medical institutions for biomedical materials (such as surgical consumables, repair and tissue engineering materials) is increasing, which is currently the focus of biological research.

The company will develop and build three business segments in the future. First, high-end surgical consumables such as clinical anti-adhesion, hemostasis, tissue repair, and embolization intervention are mainly targeted at terminal public hospitals and other markets. 2、 The series of materials for field hemostasis and first aid are mainly for the 120, social emergency rescue, family first aid and other fields. 3、 Body surface wound repair, new biomedical materials for promoting healing, disinfection products, etc. are mainly targeted at non-public medical institutions (such as private hospitals, third terminals, networks and other new channels), social channels, etc.

The company has rich experience in the research and development, approval, market application and promotion of biomedical materials, and has the ability to rapidly report the research and development results for approval, industrialization and marketing, and has a high position in the industry.

Based on its own development, the company has actively strengthened cooperation with famous scientific research institutions and relevant universities in the industry, including the Northeast University of Japan, the Russian Academy of Medical Sciences, the Shanghai Jiaotong University, Tianjin Medical University, etc., which has laid a solid foundation for the future technological development of the company's products.

Since its establishment, the company has won many honors in the industry. In 2006, the company undertook the key construction project of Hebei Province, "Biomedical Material Series Product Industrialization Project", of which the medical chitosan gel project was listed by the National Development and Reform Commission as the "National Biomedical, Biomedical Engineering High tech Industry Development Project and National Fund Subsidy Plan" in 2008. The project investment was 52.3 million yuan, which has passed the acceptance of the Hebei Development and Reform Commission; The company's "joint research and development of corn-based biomedical materials" and "joint research and development of developable chitosan embolic materials" projects were successively selected by the Ministry of Science and Technology of the People's Republic of China as the major special project of international scientific and technological cooperation of the Ministry of Science and Technology of the People's Republic of China in 2011, with an investment of more than 45 million yuan; The industrialization project of chitosan biomedical material series products was jointly reviewed by the National Development and Reform Commission and the Ministry of Industry and Information Technology as a national industrial revitalization project in 2012, with an investment of 63 million yuan.

The company pays attention to brand building, always adheres to the business philosophy of quality first and technology as the core competitiveness, and takes continuous improvement of product quality, improvement of research and development level and strengthening of market service as its corporate purpose. Looking forward to the future, Yishengtang will continue to focus on the research and development, production and sales of high-end biomedical materials, and continue to strengthen the in-depth research and development oriented by clinical needs, and the professional production based on quality as life With customer-centered marketing, we will make every effort to build the enterprise brand of "Yishengtang".